SLC5A2 and type 2 diabetes mellitus: The sodium‐glucose co‐transporter (SGLT)‐2 inhibitors, canagliflozin,2 dapagliflozin3 and empagliflozin,4 are the only glucose‐lowering agents that reduce the incidence of HF and HF‐related hospitalizations in patients with T2DM, and dapagliflozin also in patients without T2DM and established HF with reduced ejection fraction (HFrEF).5